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Edited by Christian GriesingerAbstract Alzheimer’s disease (AD) is associated with plaque
deposition in the brain of AD patients. The major component
of the aggregate is a 39–42 long peptide termed b-amyloid
(Ab). Except for Ab, plaques contain several other components
which co-precipitate together with Ab. One such component is
the small heat shock protein (sHSP) aB-crystallin. Instead of
preventing the cell from the neurotoxicity of Ab, aB-crystallin
induces an increased neurotoxicity.
We ﬁnd – using solution state NMR spectroscopy – that aB-
crystallin competes eﬃciently for Ab monomer–monomer inter-
actions. Interactions between Ab and aB-crystallin involve the
hydrophobic core residues 17–21 as well as residues 31–32 of
Ab, and thus the same chemical groups which are important
for Ab aggregation. In the presence of aB-crystallin, Met35 in
Ab becomes eﬃciently oxidized. In order to quantify the redox
properties of the diﬀerent complexes consisting of Ab/aB-crys-
tallin/copper, we suggest an NMR assay which allows to esti-
mate the electrochemical properties indirectly by monitoring
the rate of glutathion (GSH) auto-oxidation. The oxidation of
the side chain Met35 in Ab might account for the increased
neurotoxicity and the inability of Ab to form ﬁbrillar structures,
which has been observed previously in the presence of aB-crystal-
lin [Stege, G.J. et al. (1999) The molecular chaperone aB-crys-
tallin enhances amyloid-beta neurotoxicity. Biochem. Biophys.
Res. Commun. 262, 152–156.].
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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doi:10.1016/j.febslet.2006.09.063the degeneration and death of neurons in the brain regions that
are concerned with learning and memory processes [2]. It is
widely accepted that the burden of secreted and intracellular
accumulation of b-amyloid peptides (Ab) (39–43 amino acids
in length) is considered a main event in AD pathophysiology
[3,4]. Ab peptides are fragments of a 110–130 kDa type I inte-
gral membrane glycoprotein, the amyloid precursor protein
(APP), which is cleaved by a class of endoproteases termed sec-
retases [5]. The production, processing and clearance of Ab
peptides is part of the normal constitutive APP metabolism.
Profound changes in the production and/or clearance pathway
of Ab can cause disease [6]. Abnormal protein deposition is
also a shared characteristic of other late onset neurodegenera-
tive diseases, such as Parkinson’s disease, Huntington’s dis-
ease, and the Prion diseases. There is increasing evidence
that the mechanism of this seeded aggregation may be similar
in each of these diseases [7,8]. At the same time, it is found that
probably not the ﬁbrillar state, but a high oligomeric state, is
responsible for its neurotoxicity [9,10]. Protoﬁbrillar structures
are shown to be causative agents for selective neuronal deple-
tion [11,12]. So far, the molecular mechanism for neuronal
degeneration could not be identiﬁed. It is speculated that
Ab1–40 forms pores in the membrane which leads to an un-
regulated ﬂux of Ca2+ in and out of the cell [13]. Alternatively,
free radical formation [14], mitochondrial dysfunction [15] and
caspase activation [16] was suggested.
Recently, molecular chaperones were identiﬁed as binding
partners of Ab using a transgenic Caenorhabditis elegans
model to search for intracellular factors that can contribute
to neurotoxicity and metabolism of Ab [17]. Importantly, a
deranged expression proﬁle of molecular chapereones was
observed in the brain of AD patients [18]. Especially, a major
lenticular, non-tissue speciﬁc, small heat shock protein (sHsp),
aB-crystallin, was found to co-precipitate with Ab [18,19].
Further evidence for a relation between AD and aB-crystallin
stems from clinical studies which show that nearly all cases of
AD patients with trisomy-21 (Down’s syndrome) display
abnormal expression of aB-crystallin [20]. Notably, all Down’s
syndrome (DS) patients show AD pathology above 40 years of
age [21]. Additionally, the observation of frequent equatorial
supramolecular cataracts in lenses of AD patients suggests a
relation between crystallins and Ab [22]. aB-crystallin also
plays a major role in several neurological [23,24] and neuro-
muscular diseases [25,26]. The molecular mechanistic interac-
tions of aB-crystallin with Ab are, however, far from clear.blished by Elsevier B.V. All rights reserved.
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amyloid peptides and reported to inhibit ﬁbril formation
[27,28]. At the same time, it was demonstrated that preincuba-
tion of Ab with aB-crystallin yields increased neurotoxicity de-
spite reduced ﬁbril formation [1].
The current investigation was motivated by the aim to
understand the mechanism due to which aB-crystallin
increases the neurotoxicity of Ab. We identiﬁed the chemical
groups of soluble Ab1–40 that are involved in interactions with
aB-crystallin at atomic resolution using saturation transfer dif-
ference (STD) NMR experiments. Diﬀusion ordered spectro-
scopy (DOSY) and proton–proton correlation experiments
are recorded in order to monitor the oligomeric state of
Ab1–40 and conformational and constitutional changes of the
structure of Ab1–40 upon interactions with aB-crystallin,
respectively. Additionally, we developed a simple NMR assay
to characterize the redox properties of Ab1–40 upon interaction
with aB-crystallin in the presence and absence of copper. The
presented NMR experiments are comparable to experiments
carried out on the yeast prion protein Sup35 to study its
interactions to Hsp104 [29]. Our experiments show that the
interaction induce a change of the oxidation state of the
residue Met-35 in Ab1–40. We therefore speculate that aB-crys-
tallin is a redox balancing protein which interacts with the
Alzheimer’s disease peptide Ab1–40, as it turns out that the
interaction is modulated in a copper dependent manner.2. Materials and methods
2.1. Peptide synthesis and protein preparation
Ab1–40 was purchased from Biosource International, Camrillo, CA,
USA. aB-crystallin and Hsp27 are expressed recombinantly in E. coli
as we described previously [30].
2.2. Puriﬁcation of recombinant aB-crystallin
pET16b-aB-crystallin plasmid was transformed in BL21 rosetta cells
(Invitrogen). Expression of the protein was induced by 0.4 mM IPTG
for 3 h at 37 C. Cells were collected and resuspended in GET buﬀer
pH 8.0 (25 mM Tris–HCl, 2 mM EDTA, 50 mM glucose) with one
protease inhibitor cocktail tablet (Roche), and lysed by soniﬁcation.
To the lysate 5% polyethyleneimine (PEI) was slowly added to a ﬁnal
concentration of 0.12% and incubated for 10 min at room temperature.
aB-Crystallin was puriﬁed from the soluble fraction of the PEI precip-
itation by ion exchange chromotography using a fast ﬂow DEAE
sepharose and Source15Q HR 16/10 column (Amersham Pharmacia
Biotech). Size exclusion chromatography was performed on a Superose
6 HR 10/30 column in 25 mM bis Tris, pH 8.0, 150 mM NaCl with or
without 0.1 mM of copper.
2.3. Sample preparation
Ab samples were prepared by dissolving the peptide powder directly
into 450 ll of buﬀer containing 50 mM phosphate (pH 6.9) and
100 mM sodium sulphate, and 50 ll of D2O. A concentration of
Ab1–40 of 0.5 mM was used in the NMR experiments. No attempt
was made to dissolve possible aggregates before starting the experi-
ment. We could show previously that this approach yields approxi-
mately 90% (10%) of Ab1–40 in a soluble (aggregated) state [31].
2.4. CD experiments
Changes in the secondary structural content of Ab1–40 in the pres-
ence and absence of aB-crystallin as a function of time is monitored
using far-UV circular dichroism spectroscopy (CD). CD spectra were
measured using a Jasco J720 spectropolarimeter at ambient tempera-
ture. A path length of the cell of 1 mm was used. In all CD experi-
ments, 50 mM phosphate (pH 6.9) and 50 mM sodium chloride was
employed as a buﬀer. All spectra were corrected by subtracting the buf-fer base line. In order to investigate the change in secondary structure
of Ab1–40 upon addition of aB-crystallin, we incubated a 200 lM solu-
tion of Ab1–40 at 20 C together with aB-crystallin yielding a molar
ratio of 1:25 = [aB-crystallin]: [Ab1–40]. A reference experiment was
performed in order to monitor the spectral changes upon incubation
of Ab1–40 alone. The spectra are analyzed using software CONTIN
and CDSSTR [32].2.5. NMR spectroscopy
All NMR spectra were acquired at 27 C using a Bruker DMX 750
NMR equipped with a triple-resonance probe and triple-axis self-
shielded gradient coils.
2.5.1. Saturation transfer diﬀerence (STD). STD have been carried
out as described previously [29,31]. The experiment relies on the trans-
fer of saturation from the protein to the bound ligand and is based on
cross relaxation. If a ligand interacts with a protein, an attenuated
signal is observed for the free ligand after dissociation from the pro-
tein–ligand complex. Selective saturation of resonances in a protein
is possible as resonances in proteins are in general more dispersed com-
pared to the resonances of a peptide. Chemical shift separation of the
resonance signals of the protein and the interacting peptide at the point
of irradiation is a prerequisite [33]. The method has been recently used
to identify the chemical groups in a peptide ligand which is speciﬁcally
interacting with a membrane receptor [34]. The method works best for
small ligands (with fast correlation times) interacting with large protein
complexes, where the reorientation process is slow enough to give rise
to large cross relaxation rates. We employ this method to identify the
chemical groups of Ab1–40 that are involved in interactions with
aB-crystallin. In the experiments, a 500 lM and 20 lM solution of
Ab1–40 and aB-crystallin, respectively, was employed yielding a molar
ratio of 25:1 of [Ab1–40]:[aB-crystallin]. In order to retrieve exclusively
Ab1–40 Æ aB-crystallin contacts and to exclude Ab1–40 Æ Ab1–40 contacts
in the 2D-STD TOCSY experiment, FIDS from a sample containing
Ab1–40 and aB-crystallin were substracted from the FIDS recorded
for a sample containing only Ab1–40. 2D-STD-TOCSY correlation
experiments are recorded using a TOCSY mixing time of 60 ms. 512
t1 points are collected in the indirect dimension, accumulating 16 scans
per t1 increment. A train of 300 Gaussian shaped pulses with a dura-
tion of 12.5 ms using a rf ﬁeld strength of approximately 250 Hz is em-
ployed adjusting the 1H carrier frequency to 380 Hz (on-resonance)
on odd scans and to 40000 Hz (oﬀ-resonance) on even scans in order
to saturate the 1H(methyl) resonances of aB-crystallin. Subtraction of
two subsequent FIDs is achieved by incrementing the receiver phase
from scan to scan. Identiﬁcation of the entire spin systems is carried
out by a combined evaluation of TOCSY and NOESY spectra. STD
experiments were always adjusted in the ﬁrst place using a reference
peptide sample which does not undergo self-association. Furthermore,
the reference sample does not contain any target molecule to which the
peptide is supposed to bind. 1D-STD experiment carried out for these
samples did not yield signiﬁcant intensites in all cases. The perfor-
mance of the STD experiment with respect to epitope mapping was cal-
ibrated using glutathione (GSH) and glutathione-S-transferase (GST)
as a model system. The buildup of the STD ampliﬁcation factor, which
is deﬁned as the ratio of the resonance intensities for on- and oﬀ-reso-
nance irradiation of the enzyme times the molar excess of the ligand, is
steadily growing with the molar ratio of the ligand to the enzyme con-
centration. Fast STD buildup rates correspond to group epitopes that
are closer in space with respect to the enzyme binding site. In the setup
system, the Hb resonances of Cys show the fastest buildup rate which
is in agreement with interaction models for GSH and GST (data not
shown).
2.5.2. NMR redox assay. In order to assess the redox properties of
Ab1–40 and aB-crystallin, the relative rate of auto-oxidation of gluta-
thione (GSH) was determined by NMR. Auto-oxidation of GSH is
mostly due to solubilized oxygen in the sample buﬀer, but is aﬀected
by the presence of other proteins in the sample. The monomeric/
reduced (GSH) and the dimeric/oxidized (GSSG) form of glutathion
can be diﬀerentiated by their diﬀerent 1HN chemical shifts. GSH mono-
mer and GSSG dimer can be unambiguously identiﬁed by DOSY
NMR experiments. The ratio of GSSG to GSH is obtained from 1D
NMR experiments at each point in time. As a reference, the rate of
auto-oxidation of GSH was determined in the absence of any added
substance. In addition, the rate of auto-oxidation of GSH in presence
of 50 lM ascorbic acid was measured for reference. To determine the
redox behaviour of Ab1–40, a 1.0 mM solution of GSH was incubated
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crystallin. Samples were always prepared at the same time using the
same buﬀer for solubilization. All NMR tubes were capped and sealed
uniformly with paraﬁlm.3. Results
We have carried out STD NMR experiments to identify the
chemical groups of Ab1–40 which contribute to the interaction
to aB-crystallin. As we could show previously, even in the
absence of the chaperone, STD intensities are observed forFig. 1. (A) 1H 1D-STD spectrum recorded for Ab1–40 in the presence
(top) and in the absence (middle) of aB-crystallin. For reference, a 1H-
1D spectrum is represented at the bottom. The 1D-STD experiment
recorded in the presence of aB-crystallin, yields a much stronger STD
signal indicating that Ab1–40 and aB-crystallin are interacting. This
signal represents the interaction between the soluble form of Ab1–40
and aB-crystallin, since no increase in the STD signal would be
expected in case aB-crystallin interacts exclusively with the ﬁbrillar
form of Ab1–40. (B) Superimposition of a STD-TOCSY of Ab1–40 (red)
and a standard TOCSY (black), recorded in the presence of aB-
crystallin (molar ratio 1:25). The STD experiment shows only the
chemical groups that are in close proximity to the chaperone. The
spectra display the methyl and parts of the Hb spectral region only.
Amino acids from the hydrophobic core region of Ab1–40 show the
strongest STD correlations.several Ab1–40 resonances [31]. We attributed this eﬀect to
chemical exchange between Ab1–40 molecules being in the
aggregated state and the soluble state. In presence of sub-
stoichiometric amounts of aB-crystallin, STD intensities are
signiﬁcantly increased, indicating that Ab1–40 and aB-crystallin
interact (Fig. 1A).
Fig. 1B represents the aliphatic region of a 2D-STD TOCSY
spectrum, superimposed with a standard 2D-TOCSY spectrum
for reference. The interacting residues ofAb1–40 with aB-crystal-
lin are indicated in bold letters in the Ab1–40 sequence:
D1-EAFRHDSGY10-EVHHQKLVFF20-AEDVGSNKG A30-
IIGLMVGGVV40. We ﬁnd, that the region around the hydro-
phobic core (residues 17–21) contributes most to the interaction
with aB-crystallin. In addition, STD signals are observed for the
side chain resonances of the two isoleucine residues I31, I32.
In order to analyze structural changes of Ab1–40 induced by
aB-crystallin, we recorded CD spectra (Fig. 2). In the ﬁgure,
the diﬀerence of the spectrum recorded for the mixed sample
(molar ratio of Ab1–40 to aB-crystallin corresponds to 25:1)
and the spectrum recorded for aB-crystallin only is repre-
sented. For reference, the CD spectrum for Ab1–40 alone is
shown as well. Upon incubation of Ab1–40, we observe initially
a very pronounced minimum at around 218 nm which slowly
disappears and shifts towards longer wavelengths upon incu-
bation with aB-crystallin. The CD spectrum of Ab1–40 alone
does not show a signiﬁcant time dependence (data not shown).
We have previously noted variations of the CD spectrum as a
function of the salt conditions present in solution [31]. The
changes observed in the CD spectrum are as well reﬂected in
an increase of Thioﬂavin T (ThT) ﬂuoresence observed previ-
ously [1]. However, the alteration of the CD and ThT spectra
are not directly accompanied by a time dependent variation of
the NMR chemical shifts. This is in contrast to experiments
that we carried out for the N-terminal region of the prion pro-
tein in yeast, Sup355–26 interacting with the chaperone Hsp104
[29,35], where a time dependent change in the NMR spectrumFig. 2. CD diﬀerence spectra recorded for Ab1–40 in the presence and
absence of aB-crystallin. In the ﬁgure the spectrum recorded for
mixtures of Ab1–40 and aB-crystallin was subtracted from a spectrum
of a sample containing only aB-crystallin. In general, we observe that
the characteristic minimum at around 218 nm disappears as a function
of time. In the CD experiments, a concentration of 0.2 mM for Ab1–40
was employed. Otherwise, buﬀer conditions were identical to the ones
used in the NMR experiments.
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and aB-crystallin, a conformational change is induced for the
ﬁbrillar or the protoﬁbrillar state of Ab1–40, but not for the sol-
uble state.
Careful inspection of the NMR spectra, indicates the accu-
mulation of Ab1–40 molecules in which Met35 is populated in
its oxidized state (Fig. 3). The assignment of the chemical shifts
is corroborated by a recent study which has been carried out be
Zagorski and co-workers [36]. In addition, we ﬁnd that the rate
of auto-oxidation of b-mercaptoethanol is increased by a
factor of two at low temperature (7 C) and by a factor of ﬁve
at higher temperature (25 C) in the presence of aB-crystallin
(data not shown). b-mercaptoethanol was added to all samples
as a reducing agent to prevent oxidation. This led us to the
investigation of the role of the redox characteristics of aB-crys-
tallin and the implications for its interactions with Ab1–40.
In order to study the redox characteristics of the system
Ab1–40/aB-crystallin, we followed the auto-oxidation of mono-
meric glutathione (GSH) to its dimeric form (GSSG) in the ab-
sence and presence of aB-crystallin and various co-solutes by
solution state NMR spectroscopy. This simple method allows
to qualitatively determine the redox properties of proteins with
respect to reduced glutathion. If the protein which is added toFig. 3. TOCSY spectra of Ab1–40 in the presence of aB-crystallin displaying th
a function time. The spectra recorded on the ﬁrst and on the third day aft
resonances can be assigned to Met35 in its oxidized state.
Fig. 4. Auto-oxidation of GSH upon addition of Ab1–40 and aB-crystallin
oxidized to reduced glutathion I(GSSG)/I(GSH) as a function of time. As ref
in the NMR tube (circles). aB-crystallin has a reducing eﬀect on GSH (tria
oxidation of GSH, whereas Ab1–40 in combination with aB-crystallin (ﬁlled
potential for the complex of Ab1–40 and aB-crystallin in contrast to the indiv
oxidation process of GSH was recorded (stars). The concentration of GSH w
concentration of 50.0 lM and 10.0 lM, respectively.the GSH solution possesses reducing activity compared to
GSH, GSSG dimer formation occurs more slowly. We tested
this method ﬁrst using ascorbic acid as co-added substance.
As expected, a retardation of the rate of auto-oxidation of
GSH is observed in the presence of ascorbic acid (Fig. 4).
The diﬀerences of the initial rates of the GSSG dimer forma-
tion can be used in order to quantify the electrochemical
potential of a given molecule added to the GSH solution.
Fig. 4A (triangles down) represents the eﬀect of aB-crystallin
on the auto-oxidation of GSH. Addition of aB-crystallin
signiﬁcantly slows down the auto-oxidation process, whereas
Ab1–40 almost has no eﬀect (Fig. 4A, squares). A mixed sample
of Ab1–40 and aB-crystallin displays an intermediate eﬀect. If
Ab1–40 and aB-crystallin would act as independent redox
chemicals in the reaction, the same curve would be expected
as in the case where aB-crystallin was added alone to the
GSH solution. The fact that an intermediate eﬀect was
observed can only be explained by a cooperative eﬀect of the
complex of Ab1–40 and aB-crystallin. More interestingly, cop-
per has a strong eﬀect on the redox characteristics of aB-crys-
tallin (Fig. 4B). Addition of Cu(II) to GSH yields a faster
oxidation of GSH in the presence of aB-crystallin. Since Cu(II)
alone does not change the rate of auto-oxidation of GSH, wee HN-Ha region (left) and the aliphatic region (right) of the spectrum as
er incubation are colored black and red, respectively. New appearing
as monitored by NMR. The ﬁgure displays the relative intensity of
erence, we record the auto-oxidation of GSH due to solubilized oxygen
ngle down). Ab1–40 alone (squares) has almost no eﬀect on the auto-
triangles up) shows an intermediate eﬀect, indicating an altered redox
idual components. As reference, the eﬀect of ascorbic acid on the auto-
as 1.0 mM. Ascorbic acid, Ab1–40 and aB-crystallin were added using a
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redox characteristics.4. Discussion
4.1. Interaction mechanism of aB-crystallin and Ab1–40
Analysis of the 2D-STD-TOCSY experiment allows the
identiﬁcation of the chemical groups of Ab1–40 which are in-
volved in interactions with respect to aB-crystallin. We ﬁnd
that the amino acids Gln15-Asp23 and Ile31-Ile32 of Ab1–40
show especially strong interactions. These residues are located
in the hydrophobic core of Ab1–40. Fig. 1a demonstrates that
STD resonances can be observed even in the absence of the
chaperone. The observed signals are not subtraction artifacts
as the same experiment using a peptide sample which is not
prone to aggregation yields a spectrum without signals. We
could show previously that this eﬀect is due to chemical ex-
change [31]: Ab1–40 monomers are in equilibrium with Ab1–40
molecules in the aggregated state. The observed resonances re-
ﬂect the chemical groups which are involved in Ab1–40 Æ Ab1–40
interactions. Since the intensities of the 1D-STD spectrum are
much increased upon addition of aB-crystallin, we con-
clude that aB-crystallin eﬀectively competes for Ab1–40 mono-
mer–monomer interactions. This way, aB-crystallin might
destabilize Ab1–40 ﬁbril structures. This is in agreement with
ﬂuoresence studies which have shown that Ab1–40 participates
in subunit exchange of aB-crystallin which promotes Ab1–40
protoﬁbril formation [27]. DOSY experiments show that the
average molecular weight of soluble Ab1–40 is not changed
upon interaction with aB-crystallin (data not shown). Given
the fact, that we observe strong STD signals, we conclude that
the binding of monomeric Ab1–40 to aB-crystallin must be
weak and short lived. The CD spectrum represented in
Fig. 2 indicates an induced conformational change of Ab1–40
upon incubation with aB-crystallin. At the same time, the
CD spectrum of Ab1–40 alone does not change as a function
of time. Large changes in ThT ﬂuorescence were observed pre-
viously upon incubation of Ab1–40 with aB-crystallin [1], indi-
cating a structural re-organization. We interpret this ﬁnding by
suggesting that a conformational change is induced for the
ﬁbrillar or the protoﬁbrilar state of Ab1–40, but not for the
soluble state. By competing for binding to the hydrophobic
core region of Ab1–40, aB-crystallin might shift the equilibrium
between ﬁbrillar and oligomeric/protoﬁbrillar Ab1–40 more
towards the oligomeric state.
4.2. Oxidation of Ab1–40 (Met35) and reduced Ab ﬁbril
formation upon interaction with aB-crystallin
Fig. 4 shows that aB-crystallin has reducing activity with
respect to GSH. At the same time, we observe that Met35 in
Ab1–40 changes its oxidation state upon interaction with aB-
crystallin (Fig. 3). Two explanations can account for these –
at ﬁrst sight contradictory – observations: First, because of
its large size, aB-crystallin might change the redox characteris-
tics of the Ab1–40 oligomer as a whole. As shown by the 2D-
STD correlation experiment, there is no detectable interaction
between Ab1–40 (Met-35) and aB-crystallin (Fig. 1B). In a
NMR study, it was shown that this residue is not surface acces-
sible under non-oxidative conditions [37] (PDB code: 1HZ3).
We speculate that the increased diﬀerence in the redox poten-tial between the complex Ab1–40 Æ aB-crystallin and Ab1–40
alone with respect to molecular oxygen might be suﬃcient
to facilitate the oxidation of Met-35. Second, the observed
2D-STD correlations might reﬂect interactions between mono-
meric Ab1–40 and aB-crystallin. However, this second hypo-
thesis can be ruled out by the observation that NMR
chemical shift as well as the resonance intensities are not
changing over time, whereas the CD spectrum is altered.
If aB-crystallin indeed interacts with ﬁbrillar Ab1–40, how
can this interaction be observed by solution-state NMR? The
oxidized form of Ab1–40 can only be observed in solution as
a consequence of chemical exchange between the ﬁbrillar state
of Ab1–40 and a soluble state. We have previously observed
such an exchange process between Ab1–40 molecules in the
aggregated state and the soluble state [31]. This process might
be enhanced in the presence of aB-crystallin. Oxidation of
methionine induces an increased polarity by changing its di-
pole moment from 1.60 to 5.28 Debye [38]. This increased
polarity yields an increased solubility of Ab1–40 which destabi-
lizes ﬁbrillar structures [38]. This is in agreement with previous
observations which show that aB-crystallin indeed dissolves
preformed Ab1–40 ﬁbrils [1,27]. Butterﬁeld and co-worker
could show that Met35(ox) in Ab1–40 induces an increased
neurotoxicity, since the oxidized form facilitates the propaga-
tion of free radicals among adjacent residues [39]. Recent
experiments suggest that probably not the ﬁbrillar state, but
a high oligomeric state of Ab1–40 is responsible for its neuro-
toxicity [9–11].5. Conclusion
Taken together, we conclude that Ab1–40 interacts with aB-
crystallin through its hydrophobic core residues 17–24. As a
result of this interaction, the residue Met35 of Ab1–40 becomes
oxidized. The oxidation of Met35 is a consequence of the
redox properties induced by aB-crystallin and might be the
reason for the increased neurotoxicity of Ab and the inability
to form ﬁbrillar structure in the presence of aB-crystallin.
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